Spots Global Cancer Trial Database for herceptin
Every month we try and update this database with for herceptin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | NCT00337649 | Breast Cancer | Epothilone D Herceptin | 18 Years - | Hoffmann-La Roche | |
| A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | NCT00545688 | Breast Cancer | Herceptin Docetaxel Pertuzumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | NCT00337649 | Breast Cancer | Epothilone D Herceptin | 18 Years - | Hoffmann-La Roche | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Prognostic and Predictive Factors for Small Breast Tumors | NCT03390608 | Breast Cancer | Endocrine thera... Radiotherapy Herceptin Chemotherapy Type of breast ... Age at diagnosi... Screen detected... Menopausal stat... Tumor size Estrogen recept... Tumor grade HER2-status Intrinsic subgr... Nodal status | - 100 Years | Karolinska Institutet | |
| microRNA of Human Epidermal Growth Factor Receptor 2 ļ¼HER2ļ¼Positive Patient Treated With Herceptin | NCT02656589 | Breast Cancer | Capecitabine Trastuzumab | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Experience of the Patient Treated With Trastuzumab (Herceptin Ā®) as Adjuvant for Breast Cancer | NCT01400438 | Breast Cancer | questionnaires questionnaires | 18 Years - | Centre Francois Baclesse | |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With HerceptinĀ® in Healthy Male Volunteers | NCT05765357 | Metastatic Brea... Metastatic Gast... | Trastuzumab for... Herceptin | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study Of PF-05280014 Or Trastuzumab Plus TaxotereĀ® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 TaxotereĀ® ParaplatinĀ® Trastuzumab-EU TaxotereĀ® ParaplatinĀ® | 18 Years - | Pfizer | |
| Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | NCT00317720 | Breast Cancer Neoplasm Metast... | Trastuzumab RAD001 | 18 Years - | M.D. Anderson Cancer Center | |
| A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females | NCT00800436 | Breast Cancer | Herceptin | 18 Years - | Hoffmann-La Roche | |
| Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer | NCT01928589 | Breast Cancer Adenocarcinoma ... | PBI with sequen... PBI with concur... | 18 Years - 100 Years | Indiana University | |
| Strain Imaging in Breast Cancer Patients Receiving Trastuzumab | NCT02080390 | Her 2 Positive ... | Transthoracic e... | 18 Years - | University of Florida | |
| Adj TC + Herceptin Early Stage Breast Cancer | NCT00493649 | Breast Cancer | Taxotere Cytoxan Herceptin | 18 Years - 70 Years | US Oncology Research | |
| Evaluate Safety, Efficacy and Pharmacokinetics | NCT01084863 | Metastatic Brea... | CT-P6 Herceptin Paclitaxel | 18 Years - | Celltrion | |
| Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients | NCT00806507 | Breast Cancer | Echocardiograms Blood Test | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Herceptin in Patients With Breast Cancer | NCT00133796 | BREAST CANCER | Herceptin | 18 Years - 90 Years | Baylor Breast Care Center | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | NCT03433313 | Breast Cancer | EG12014 Herceptin | 18 Years - 65 Years | EirGenix, Inc. | |
| Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer | NCT00071357 | Breast Neoplasm... | - | National Institutes of Health Clinical Center (CC) | ||
| Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) | NCT00095706 | Breast Cancer | Bevacizumab (dr... | 18 Years - 75 Years | Translational Oncology Research International | |
| Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | NCT00440622 | Breast Cancer | Gemcitabine Herceptin Capecitabine (X... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | NCT01649271 | Breast Neoplasm... Stomach Neoplas... | Herceptin afatinib trastuzumab Herceptin afatinib afatinib | 18 Years - 99 Years | Boehringer Ingelheim | |
| Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | NCT00146549 | Breast Cancer Stage IV Breast... | Trastuzumab Vinorelbine Paclitaxel Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | NCT01480583 | Breast Cancer Brain Metastase... | GRN1005 Trastuzumab 18F-FLT | 18 Years - | Angiochem Inc | |
| A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | NCT00391092 | Breast Cancer | bevacizumab [Av... Docetaxel Herceptin | 18 Years - | Hoffmann-La Roche | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to HerceptinĀ® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| microRNA of Human Epidermal Growth Factor Receptor 2 ļ¼HER2ļ¼Positive Patient Treated With Herceptin | NCT02656589 | Breast Cancer | Capecitabine Trastuzumab | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer | NCT01084876 | Metastatic Brea... | CT-P6 Herceptin Paclitaxel | 18 Years - | Celltrion | |
| Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | NCT01570036 | Breast Cancer | Herceptin NeuVax vaccine GM-CSF | 18 Years - | Cancer Insight, LLC | |
| A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | NCT02748213 | Breast Cancer | Xeloda Taxotere Herceptin | 18 Years - | Hoffmann-La Roche | |
| Adj TC + Herceptin Early Stage Breast Cancer | NCT00493649 | Breast Cancer | Taxotere Cytoxan Herceptin | 18 Years - 70 Years | US Oncology Research | |
| Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | NCT00372424 | Breast Cancer | Herceptin Sunitinib Taxotere | 18 Years - | Pfizer | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | NCT02025192 | HER2 Positive M... | Tucatinib Capecitabine Trastuzumab | 18 Years - | Seagen Inc. | |
| Neoadjuvant Herceptin in Patients With Breast Cancer | NCT00133796 | BREAST CANCER | Herceptin | 18 Years - 90 Years | Baylor Breast Care Center | |
| Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases | NCT01004172 | Metastatic Brea... Breast Cancer Progressive Bre... | carboplatin bevacizumab herceptin | 18 Years - | Dana-Farber Cancer Institute | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | NCT00138125 | Breast Cancer | Faslodex Herceptin | 18 Years - | Translational Oncology Research International | |
| Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | NCT00004067 | Breast Cancer | herceptin adriamycin cyclophosphamid... taxol | 18 Years - | NSABP Foundation Inc | |
| Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer | NCT00118053 | Breast Cancer | herceptin carboplatin docetaxel conventional su... radiation thera... | 18 Years - | Rutgers, The State University of New Jersey | |
| Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases | NCT01004172 | Metastatic Brea... Breast Cancer Progressive Bre... | carboplatin bevacizumab herceptin | 18 Years - | Dana-Farber Cancer Institute | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | NCT00453635 | Breast Cancer | Docetaxel Carboplatin Herceptin Vinorelbine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer | NCT01928589 | Breast Cancer Adenocarcinoma ... | PBI with sequen... PBI with concur... | 18 Years - 100 Years | Indiana University | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (HerceptinĀ®) and Docetaxel (TaxotereĀ®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | NCT00004067 | Breast Cancer | herceptin adriamycin cyclophosphamid... taxol | 18 Years - | NSABP Foundation Inc | |
| Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin Ā®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging | NCT01436604 | Cancer, Breast LV Dysfunction | Cardiac MRI | 18 Years - | Centre Francois Baclesse | |
| Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | NCT01479179 | Breast Cancer | AMG 479 Trastuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | NCT00038402 | Breast Cancer | Herceptin Taxol Fluorouracil Cytoxan Epirubicin | - | M.D. Anderson Cancer Center | |
| Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | NCT00440622 | Breast Cancer | Gemcitabine Herceptin Capecitabine (X... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | NCT00470704 | Breast Cancer | Lapatinib Herceptin | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluate Safety, Efficacy and Pharmacokinetics | NCT01084863 | Metastatic Brea... | CT-P6 Herceptin Paclitaxel | 18 Years - | Celltrion | |
| Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | NCT03879577 | Breast Cancer Breast Cancer F... HER2-positive B... Breast Cancer S... Breast Cancer S... | Docetaxel Herceptin FEC Tamoxifen Letrozole LHRH agonist | 18 Years - 70 Years | University of Chicago | |
| Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | NCT01570036 | Breast Cancer | Herceptin NeuVax vaccine GM-CSF | 18 Years - | Cancer Insight, LLC | |
| Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | NCT00458237 | Breast Cancer | Everolimus Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | NCT00078572 | Breast Cancer | capecitabine lapatinib (GW57... | 18 Years - | GlaxoSmithKline | |
| Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients | NCT02062983 | Breast Cancer | Herceptin | 18 Years - 80 Years | National Guard Health Affairs | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin Ā® | NCT04905667 | Breast Cancer | GB221 Herceptin | 18 Years - 45 Years | Genor Biopharma Co., Ltd. | |
| Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis | NCT02380131 | HER-2 Positive ... Liver Metastasi... | Oxaliplatin plu... Herceptin | 18 Years - 75 Years | Hebei Medical University | |
| Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer | NCT00943410 | Breast Cancer | external beam r... Herceptin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | NCT03161353 | Breast Cancer | Perjeta Herceptin Docetaxel Carboplatin Letrozole Tamoxifen | 18 Years - | MedSIR | |
| Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | NCT05301530 | Breast Cancer M... Breast Cancer F... Breast Cancer R... | Faceptor Herceptin Docetaxel | 18 Years - 65 Years | Nanogen Pharmaceutical Biotechnology Joint Stock Company | |
| Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | NCT01401166 | Breast Neoplasm... | Herceptin Herceptin Single-Use Inje... Single-Use Inje... | 18 Years - | Hoffmann-La Roche | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer | NCT00191451 | Breast Cancer | Gemcitabine Carboplatin Herceptin | 18 Years - | Eli Lilly and Company | |
| Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer | NCT03907800 | Breast Cancer Triple Negative... HER2-positive B... | Nab-paclitaxel Carboplatin Herceptin | 18 Years - | Ruijin Hospital | |
| Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | NCT00041470 | Breast Cancer | Paclitaxel Vinorelbine Herceptin Filgrastim | 18 Years - | University of Washington | |
| A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01) | NCT01603264 | Healthy | PF-05280014 Herceptin Herceptin | 18 Years - 55 Years | Pfizer | |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With HerceptinĀ® in Healthy Male Volunteers | NCT05765357 | Metastatic Brea... Metastatic Gast... | Trastuzumab for... Herceptin | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer | NCT03989037 | HER2-positive E... | SIBP-01 Herceptin Docetaxel Carboplatin | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression | NCT00943670 | Metastatic Brea... | pertuzumab Trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | NCT02748213 | Breast Cancer | Xeloda Taxotere Herceptin | 18 Years - | Hoffmann-La Roche | |
| Study of Larotaxel in Combination With Weekly HerceptinĀ® in Patients With HER2 Positive Metastatic Breast Cancer | NCT00387907 | Advanced Breast... Breast Cancer Metastatic Brea... | larotaxel (XRP9... trastuzumab | 18 Years - | Sanofi | |
| Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | NCT00470704 | Breast Cancer | Lapatinib Herceptin | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to HerceptinĀ® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
